FDA highlights concerns with compounding of drug products by medical offices and clinics under insanitary conditions (2021)

Government Record · U.S. Food and Drug Administration, Center for Drug Evaluation and Research · October 26, 2021

U.S. Food et al., 2021-10-26: FDA page warning that medical offices and clinics, including retail IV hydration clinics, medical spas and mobile IV services, compound sterile drugs under insanitary conditions without adequate sterility assurance.

FDA has also become aware of business models, such as intravenous (IV) hydration clinics, medical spas, and mobile IV infusion services, that are compounding drugs that may not

Body text (undated web page; no pagination)

U.S. Food et al., 2021-10-26: FDA page warning that medical offices and clinics, including retail IV hydration clinics, medical spas and mobile IV services, compound sterile drugs under insanitary conditions without adequate sterility assurance. Study type: regulatory record.